Showing results (71-80 of 295) with videos related to
Sort By:
Pageof 30
Current Opinion in Pharmacology|June 29, 2015
Drugging PI3K in cancer: refining targets and therapeutic strategiesTimothy A Yap, Lynn Bjerke, Paul A Clarke, et al.Molecular Cancer Therapeutics|April 1, 2008
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitorsUdai Banerji, Annette Affolter, Ian Judson, et al.Cancer Research|February 19, 2008
Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycinJoanna L Holmes, Swee Y Sharp, Steve Hobbs, et al.Current Pharmaceutical Design|September 28, 2016
Polypharmacology in Precision Oncology: Current Applications and Future ProspectsAlbert A Antolin, Paul Workman, Jordi Mestres, et al.Plos Computational Biology|December 25, 2015
Distinctive Behaviors of Druggable Proteins in Cellular NetworksCostas Mitsopoulos, Amanda C Schierz, Paul Workman, et al.Biotechniques|May 10, 2021
Tumor cell invasion into Matrigel: optimized protocol for RNA extractionRoberta Ferretti, Antonella Baldassarre, Emmanuel de Billy, et al.Diagnostics (Basel, Switzerland)|September 23, 2022
Pediatric Diffuse Midline Gliomas: An Unfinished PuzzleValentina Di Ruscio, Giada Del Baldo, Francesco Fabozzi, et al.Cellular Signalling|January 14, 2018
Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signallingMichael D Bright, Paul A Clarke, Paul Workman, et al.Cell|February 11, 2017
How Much Longer Will We Put Up With $100,000 Cancer Drugs?Paul Workman, Giulio F Draetta, Jan H M Schellens, et al.Journal of Biomolecular Screening|July 10, 2012
Small-molecule inhibitors of the protein methyltransferase SET7/9 identified in a high-throughput screenNicola-Jane Francis, Martin Rowlands, Paul Workman, et al.Pageof 30